Zhao Ran, Sun Junfeng, Qi Tianming, Zhao Wen, Han Zongxi, Yang Xiaopu, Liu Shengwang
Division of Avian Infectious Diseases, State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, The Chinese Academy of Agricultural Sciences, Harbin 150069, People's Republic of China; College of Veterinary Medicine, Gansu Agricultural University, Lanzhou 730070, People's Republic of China.
Division of Avian Infectious Diseases, State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, The Chinese Academy of Agricultural Sciences, Harbin 150069, People's Republic of China.
Vaccine. 2017 Apr 25;35(18):2435-2442. doi: 10.1016/j.vaccine.2017.03.045. Epub 2017 Mar 22.
The recombinant LaSota strain expressing a chimeric IBV S1 gene (rLaSota-S1) was constructed with the S1 gene of the LX4 type IBV ck/CH/LDL/091022. The expression of the S1 protein was detected by an indirect immunofluorescence assay and Western blotting. The rLaSota-S1 strain was slightly attenuated, and its growth dynamics were similar to that of the parental LaSota strain. Vaccination of specific pathogen-free chickens with the rLaSota-S1 strain induced NDV hemagglutination inhibition antibodies, and it protected chickens from challenge with virulent NDV. In addition, vaccination with the rLaSota-S1 strain induced IBV-specific IgG antibodies and cellular immunity; however, a single vaccination provided partial protection with reduced virus shedding. Better protection efficiency was observed after a booster vaccination, which resulted in higher antibody titers, significantly fewer disease symptoms, and reduced virus replication and shedding. Our results suggest that the rLaSota-S1 strain is a bivalent vaccine candidate against both NDV and IBV.
用LX4型传染性支气管炎病毒（IBV）ck/CH/LDL/091022的S1基因构建了表达嵌合IBV S1基因的重组LaSota株（rLaSota-S1）。通过间接免疫荧光试验和蛋白质免疫印迹法检测S1蛋白的表达。rLaSota-S1株有轻微的减毒，其生长动力学与亲本LaSota株相似。用rLaSota-S1株对无特定病原体鸡进行疫苗接种可诱导新城疫病毒（NDV）血凝抑制抗体，并保护鸡免受强毒NDV的攻击。此外，用rLaSota-S1株进行疫苗接种可诱导IBV特异性IgG抗体和细胞免疫；然而，单次接种仅提供部分保护，病毒排出量减少。加强免疫后观察到更好的保护效果，产生了更高的抗体滴度，疾病症状显著减少，病毒复制和排出量降低。我们的结果表明，rLaSota-S1株是一种针对NDV和IBV的双价疫苗候选株。
